This 2005 review by Liu et al. explores the potential of nanoparticle-conjugated chelators as a novel therapeutic strategy for Alzheimer's disease (AD). Traditional chelation therapies, such as desferrioxamine, have shown limited efficacy due to poor blood-brain barrier (BBB) permeability and systemic side effects. The authors propose that nanoparticles conjugated to
